rs2747648 — ESR1 ESR1 3′UTR miR-453 site

ESR1 3′UTR Variant — Estrogen Receptor Expression, Breast Cancer Risk, and Reproductive Aging

Estrogen receptor alpha (ERα), encoded by ESR1 on chromosome 6, is the master mediator of estrogen's effects throughout the reproductive system, skeleton, breast, and cardiovascular tissues. ERα regulates the timing of puberty and menopause, drives follicular development in the ovary, governs endometrial proliferation, and controls hypothalamic feedback that synchronizes the HPG axis. Because so much of female reproductive biology runs through this single receptor, polymorphisms that alter how much ERα is made — or how well it responds to estrogen — can shift the timing and quality of reproductive aging in consequential ways.

rs2747648 sits in the 3′ untranslated region (3′UTR) of ESR1, a stretch of the mRNA transcript that does not encode protein but contains regulatory sequences that govern how efficiently the mRNA is translated and how quickly it is degraded. One key class of 3′UTR regulators is microRNAs¹¹ microRNAs
small non-coding RNA molecules, approximately 22 nucleotides long, that bind to complementary sequences in mRNA 3′UTRs and suppress protein production by blocking translation or triggering mRNA degradation.

The Mechanism

The rs2747648 variant creates or disrupts a binding site for miR-453²² miR-453
microRNA-453, a small regulatory RNA expressed in reproductive and breast tissues that targets ESR1 mRNA for translational repression. Computational analysis confirmed experimentally by Tchatchou et al. 2009³³ Tchatchou et al. 2009
Carcinogenesis — familial breast cancer study of miRNA target site SNPs in cancer-related genes showed that the C allele strengthens miR-453 binding affinity, allowing miR-453 to more effectively suppress ESR1 mRNA translation. The result: lower ERα protein levels in cells carrying the C allele.

The T allele (the allele carried by ~97% of people globally) weakens miR-453 binding. ESR1 mRNA is less efficiently repressed, yielding higher baseline ERα protein levels. This is the population-typical state — most people have TT and average ERα expression at this locus.

Higher ERα levels, while normal, are not neutral for all tissue contexts: in breast epithelium, estrogen receptor signaling drives cellular proliferation, and elevated receptor abundance is a recognized driver of estrogen-dependent breast cancer, particularly in premenopausal women when estrogen levels are highest.

The Evidence

The primary evidence for rs2747648 comes from a familial breast cancer study⁴⁴ familial breast cancer study
Tchatchou et al. Carcinogenesis 2009; analysis of 11 miRNA target site SNPs across a large familial cohort that identified significant association with premenopausal breast cancer risk. Women carrying at least one C allele had OR = 0.60 (95% CI 0.41–0.89, p=0.010) for premenopausal breast cancer compared to TT homozygotes — a 40% reduction in relative risk. The protective effect was even stronger in high-risk familial cases (OR = 0.42, 95% CI 0.25–0.71, p=0.0009).

The fertility and reproductive aging implications of this variant are inferred from the broader ESR1 locus literature. Multiple studies have linked ESR1 polymorphisms to premature ovarian failure (POF) and age at natural menopause. Schuh-Huerta et al. 2012⁵⁵ Schuh-Huerta et al. 2012
Orphanet Journal of Rare Diseases — ESR1 variants associated with both age at natural menopause and premature ovarian failure in independent cohorts showed that nearby ESR1 variants (rs2234693) are significantly associated with both age at menopause and POF risk — consistent with a shared genetic architecture across the ESR1 locus. Cordts et al. 2012⁶⁶ Cordts et al. 2012
Journal of Assisted Reproduction and Genetics — ESR1 PvuII polymorphism associated with POF under a recessive model, p=0.034, in Brazilian women with n=70 POF cases and 73 controls and Yang et al. 2010⁷⁷ Yang et al. 2010
Journal of Women's Health — ESR1 XbaI/PvuII haplotypes modify POF risk; X allele OR 0.6 for idiopathic POF in Korean women further confirm ESR1's role in setting the pace of ovarian aging.

The C allele's impact on ESR1 expression in reproductive tissues has not been directly studied in ovarian or endometrial biopsies for this specific variant. The connection to reproductive function is mechanistically plausible (lower ERα in ovarian follicles and hypothalamic neurons could alter folliculogenesis and GnRH feedback) but is classified as emerging evidence for this specific rsid.

Practical Implications

For the rare individuals (approximately 1 in 20) who carry the C allele (CT or CC), the primary implication is a genetically lower risk of premenopausal breast cancer, driven by reduced ERα abundance. For CT heterozygotes — the dominant non-normal genotype — the effect is partial.

The fertility implications of reduced ERα expression are less well characterized for this specific variant. In animal models, loss of ERα function consistently disrupts follicular maturation, ovulation, and hypothalamic GnRH pulsatility. Whether the modest reduction in ERα expected from one C allele at this regulatory site has any measurable effect on ovarian reserve or menopause timing is not established from direct studies of rs2747648. Monitoring reproductive hormone levels (FSH, AMH, estradiol) provides the most actionable pathway if concerns arise.

Interactions

rs2747648 is in physical proximity to several well-studied ESR1 variants, including rs2234693 (PvuII, intron 1)⁸⁸ rs2234693 (PvuII, intron 1)
ESR1 polymorphism associated with endometrial receptivity, bone density, and POF risk in multiple cohorts, rs9340799 (XbaI, intron 1)⁹⁹ rs9340799 (XbaI, intron 1)
ESR1 variant associated with endometriosis-related infertility and IVF failure, and rs1159327 (intron variant, associated with bone mineral density). Haplotype effects across these variants are likely, since they span the regulatory introns that control ERα tissue-specific expression.